ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Global Investigative Sites Recognize Parexel with the 2023 Society for Clinical Research Sites Eagle Award

DURHAM, N.C., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced it has been awarded the 2023 Society for Clinical Research Sites (SCRS) Eagle Award (CRO category). Parexel received the award at the annual Global Site Solutions Summit held Oct. 6-8 in Hollywood, Fla. The SCRS Eagle Award recognizes the sponsor and CRO committed to outstanding leadership, professionalism, integrity, passion and dedication to advancing the clinical research profession through strong site partnerships.

“Parexel’s collaboration with sites is fundamental to the drug development process and our ability to better serve patients,” said Teri Karcher, Ph.D., Executive Vice President, Head of Launch Excellence & Chief Drug Development Officer. “We are tremendously proud to receive this year’s Eagle Award, which was made possible by the significant contributions and dedication of Parexel’s global site-facing and site supporting teams.”

In support of strong site relationships, Parexel maintains a Site Alliance Network to address the most critical challenges in the clinical trial pathway, create predictable and successful patient recruitment strategies, and expand clinical trial opportunities to investigators and patients across a broader geographical footprint. The company’s Site Alliance Network includes more than 480 sites consisting of more than 21,000 site investigators globally.

Through its ongoing and active collaboration in SCRS, Parexel contributes to a number of different initiatives focused on site and patient support to drive improvements across the clinical development process, including:

  • Leading a Site Advocacy Group focused on bringing sites and patients together to discuss patient perceptions and opportunities to reduce burdens in clinical trials.
  • Conducting country-specific Site Alliance Forums with site investigators and coordinators to discuss pain points and develop solutions.
  • Hosting quarterly forums (Parexel Site Pulse) for global site representatives to learn from other sites and make more informed decisions, and inform Parexel decisions to ensure the best outcome for patients and sites.
  • Participating as an SCRS Global Impact Partner with sites, sponsors, CROs and professional service providers who facilitate a unique opportunity to engage with SCRS and its members.  

SCRS is the leading advocacy organization with a mission to unify the voice of the global clinical research site community. The Eagle Award selection criteria included willingness to collaborate on protocol design and execution, availability of staff to support sites, responsive communication, and fair contracting, budgeting, and payment schedules. The clinical research site community globally ranked companies they had worked with in the past year that they felt exemplified these characteristics. The sponsor and CRO recipients were selected based on the overall number of votes cast by the global site community.

Parexel’s receipt of the SCRS Eagle Award follows its recognition earlier this year as the “Top CRO to Work With” in the WCG CenterWatch Global Investigative Site Relationship survey. This was the second straight time Parexel received the highest ranking in the biannual survey. Among the 34 CROs included in the survey, Parexel received the highest average rating across all 26 performance attributes evaluated.

About Parexel
Parexel is among the world’s largest clinical research organizations (CROs), providing the full range of Phase I to IV clinical development services to help life-saving treatments reach patients faster. Leveraging the breadth of our clinical, regulatory and therapeutic expertise, our team of more than 21,000 global professionals works in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind, increasing access and participation to make clinical research a care option for anyone, anywhere. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas, while our innovation ecosystem offers the best solutions to make every phase of the clinical trial process more efficient. With the people, insight and focus on operational excellence, we work With Heart™ every day to treat patients with dignity and continuously learn from their experiences, so every trial makes a difference. For more information, visit parexel.com and follow us on LinkedIn, Twitter,Facebook and Instagram

MEDIA
Lori Preuit Dorer
Senior Vice President, Corporate Communications
+1 513 496 8121
Lori.Dorer@parexel.com

Danaka Williams
Director, Corporate Communications
+1 984 298 4207
Danaka.Williams@parexel.com


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  229.53
+0.42 (0.18%)
AAPL  278.78
-1.92 (-0.68%)
AMD  217.97
+1.99 (0.92%)
BAC  53.95
+0.07 (0.13%)
GOOG  322.09
+3.70 (1.16%)
META  673.42
+11.89 (1.80%)
MSFT  483.16
+2.32 (0.48%)
NVDA  182.41
-0.97 (-0.53%)
ORCL  217.58
+3.25 (1.52%)
TSLA  455.00
+0.47 (0.10%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.